ADMA Biologics Inc (NASDAQ:ADMA) Receives Average Rating of “Hold” from Brokerages

ADMA Biologics Inc (NASDAQ:ADMA) has earned a consensus rating of “Hold” from the six brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $18.6667.

ADMA has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Zacks Research downgraded shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 4th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Raymond James Financial initiated coverage on shares of ADMA Biologics in a research note on Wednesday, June 10th. They set an “outperform” rating and a $21.00 target price for the company. Finally, Canaccord Genuity Group reduced their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 7th.

Institutional Investors Weigh In On ADMA Biologics

Several large investors have recently made changes to their positions in ADMA. Royal Bank of Canada increased its holdings in shares of ADMA Biologics by 448.8% in the 1st quarter. Royal Bank of Canada now owns 929,326 shares of the biotechnology company’s stock worth $8,373,000 after buying an additional 759,984 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of ADMA Biologics by 107.5% in the 1st quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock valued at $36,019,000 after acquiring an additional 2,071,338 shares during the last quarter. Calamos Advisors LLC grew its position in ADMA Biologics by 120.0% in the fourth quarter. Calamos Advisors LLC now owns 292,426 shares of the biotechnology company’s stock worth $5,334,000 after acquiring an additional 159,501 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in ADMA Biologics in the first quarter worth about $951,000. Finally, BNP Paribas Financial Markets grew its position in ADMA Biologics by 2,188.4% in the fourth quarter. BNP Paribas Financial Markets now owns 1,141,106 shares of the biotechnology company’s stock worth $20,814,000 after acquiring an additional 1,091,241 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $9.76 on Friday. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of 13.94 and a beta of 0.74. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49. The stock’s 50-day simple moving average is $8.93 and its 200-day simple moving average is $10.80. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. The firm had revenue of $124.39 million during the quarter, compared to analysts’ expectations of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The firm’s revenue was up 2.0% on a year-over-year basis. During the same quarter last year, the business posted $0.14 earnings per share. As a group, analysts expect that ADMA Biologics will post 0.78 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.